HOME ·

AstraZeneca

CSPC PHARMA(01093.HK): Receives USD10‑Million Milestone Payment from AstraZeneca
Tags：
CSPC PHARMA01093.HKAstraZenecastrategic cooperation
2026-08-05
CSPC PHARMA(01093.HK): Joint Venture Established with AstraZeneca, Holding 51% Stake to Co‑Build Biologics Manufacturing Base
Tags：
CSPC PHARMA01093.HKAstraZenecajoint‑venture company
2026-08-05
KEYMED BIO-B (02162.HK): Global Phase III Trial of CMG901 (AZD0901) Meets Primary Endpoint, Delivers Improved OS for 2L+ Gastric Cancer; AstraZeneca Forecasts Peak Sales of USD3-5 Billion
Tags：
KEYMED BIO-B02162.HKAstraZenecaClinical Trial
2026-07-28
LEPU BIO (02157.HK): Global Phase III Trial of CMG901 Meets Primary Endpoint, Significantly Improves Overall Survival of CLDN18.2-positive Advanced Gastric Cancer Patients
Tags：
LEPU BIO02157.HKAstraZenecaClinical Trial
2026-07-28
SINO BIOPHARM(01177.HK): Exclusive Licensing Agreement with AstraZeneca for TQC3721, USD200 Million Upfront Payment plus Up to USD1.9 Billion Milestones
Tags：
SINO BIOPHARM01177.HKAstraZenecacooperation
2026-07-08
CSPC PHARMA(01093.HK): Enters Collaboration, Option and Licence Agreement with AstraZeneca for siRNA Drug Development with USD30 Million Upfront Payment
Tags：
CSPC PHARMA01093.HKAstraZeneca
2026-07-02